{"id": "UgD1uFgAAAAJ", "citedby": 4056, "citedby5y": 2718, "hindex": 29, "hindex5y": 23, "i10index": 50, "i10index5y": 42, "coauthors": [], "name": "Justin Kline", "affiliation": "Associate Professor of Medicine", "interests": ["Tumor immunology"], "cites_per_year": {"2006": 16, "2007": 58, "2008": 59, "2009": 96, "2010": 122, "2011": 135, "2012": 203, "2013": 300, "2014": 317, "2015": 325, "2016": 415, "2017": 476, "2018": 510, "2019": 650, "2020": 329}, "publications": [{"bib": {"title": "Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8\u03b1+ dendritic cells", "year": "2011"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:aqlVkmm33-oC", "citedby": "669"}, {"bib": {"title": "Immune resistance orchestrated by the tumor microenvironment", "year": "2006"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:dfsIfKJdRG4C", "citedby": "420"}, {"bib": {"title": "PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model", "year": "2009"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:M3NEmzRMIkIC", "citedby": "320"}, {"bib": {"title": "CD47 blockade triggers T cell\u2013mediated destruction of immunogenic tumors", "year": "2015"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:bFI3QPDXJZMC", "citedby": "271"}, {"bib": {"title": "Costimulatory and coinhibitory receptors in anti\u2010tumor immunity", "year": "2009"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:SeFeTyx0c_EC", "citedby": "224"}, {"bib": {"title": "CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma", "year": "2018"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:pqnbT2bcN3wC", "citedby": "166"}, {"bib": {"title": "Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions", "year": "2011"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:NhqRSupF_l8C", "citedby": "155"}, {"bib": {"title": "Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment", "year": "2011"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:tOudhMTPpwUC", "citedby": "134"}, {"bib": {"title": "Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients", "year": "2014"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:BrmTIyaxlBUC", "citedby": "129"}, {"bib": {"title": "Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma", "year": "2008"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:K3LRdlH-MEoC", "citedby": "93"}, {"bib": {"title": "Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection", "year": "2006"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:GnPB-g6toBAC", "citedby": "93"}, {"bib": {"title": "Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.", "year": "2010"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:hC7cP41nSMkC", "citedby": "69"}, {"bib": {"title": "PD\u20101 regulates extrathymic regulatory T\u2010cell differentiation", "year": "2014"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:5Ul4iDaHHb8C", "citedby": "66"}, {"bib": {"title": "Leukemia cell\u2013targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity", "year": "2014"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:pyW8ca7W8N0C", "citedby": "66"}, {"bib": {"title": "Immune evasion in acute myeloid leukemia: current concepts and future directions", "year": "2013"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:BqipwSGYUEgC", "citedby": "65"}, {"bib": {"title": "STING pathway activation stimulates potent immunity against acute myeloid leukemia", "year": "2016"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:RHpTSmoSYBkC", "citedby": "56"}, {"bib": {"title": "Dendritic cells coordinate the development and homeostasis of organ-specific regulatory T cells", "year": "2016"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:Se3iqnhoufwC", "citedby": "56"}, {"bib": {"title": "Therapeutic activity of high-dose intratumoral IFN-\u03b2 requires direct effect on the tumor vasculature", "year": "2014"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:f2IySw72cVMC", "citedby": "50"}, {"bib": {"title": "Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes", "year": "2005"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:WF5omc3nYNoC", "citedby": "50"}, {"bib": {"title": "Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance", "year": "2008"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:8k81kl-MbHgC", "citedby": "46"}, {"bib": {"title": "Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning", "year": "2006"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:IWHjjKOFINEC", "citedby": "46"}, {"bib": {"title": "CD40 ligation reverses T cell tolerance in acute myeloid leukemia", "year": "2013"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:4OULZ7Gr8RgC", "citedby": "45"}, {"bib": {"title": "A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T\u2010cell lymphomas", "year": "2013"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:UebtZRa9Y70C", "citedby": "44"}, {"bib": {"title": "Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation", "year": "2012"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:TQgYirikUcIC", "citedby": "43"}, {"bib": {"title": "Gene expression profiles in acute myeloid leukemia with common translocations using SAGE", "year": "2006"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:vV6vV6tmYwMC", "citedby": "40"}, {"bib": {"title": "Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity", "year": "2018"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:P5F9QuxV20EC", "citedby": "39"}, {"bib": {"title": "Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation", "year": "2012"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:HDshCWvjkbEC", "citedby": "36"}, {"bib": {"title": "Mechanisms of immune tolerance in leukemia and lymphoma", "year": "2017"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:tS2w5q8j5-wC", "citedby": "31"}, {"bib": {"title": "Targeting the innate immune system as immunotherapy for acute myeloid leukemia", "year": "2015"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:9yKSN-GCB0IC", "citedby": "29"}, {"bib": {"title": "Immune reconstitution after combined haploidentical and umbilical cord blood transplant", "year": "2013"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:kNdYIx-mwKoC", "citedby": "25"}, {"bib": {"title": "Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review", "year": "2005"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:V3AGJWp-ZtQC", "citedby": "25"}, {"bib": {"title": "A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin's lymphoma", "year": "2013"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:OU6Ihb5iCvQC", "citedby": "22"}, {"bib": {"title": "PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation", "year": "2017"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:eflP2zaiRacC", "citedby": "21"}, {"bib": {"title": "Emerging role of checkpoint blockade therapy in lymphoma", "year": "2017"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:iH-uZ7U-co4C", "citedby": "21"}, {"bib": {"title": "Highly clonal regulatory T-cell population in follicular lymphoma \u2013 inverse correlation with the diversity of CD8+ T cells", "year": "2015"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:LPZeul_q3PIC", "citedby": "20"}, {"bib": {"title": "Update on checkpoint blockade therapy for lymphoma", "year": "2015"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:ZHo1McVdvXMC", "citedby": "17"}, {"bib": {"title": "Correlation of T-cell inflamed phenotype with mesenchymal subtype, expression of PD-L1, and other immune checkpoints in head and neck cancer.", "year": "2014"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:70eg2SAEIzsC", "citedby": "17"}, {"bib": {"title": "Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results.", "year": "2018"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:vRqMK49ujn8C", "citedby": "16"}, {"bib": {"title": "T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia", "year": "2015"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:zA6iFVUQeVQC", "citedby": "15"}, {"bib": {"title": "Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia", "year": "2009"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:zYLM7Y9cAGgC", "citedby": "15"}, {"bib": {"title": "Influence of related donor age on outcomes after peripheral blood stem cell transplantation", "year": "2012"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:J-pR_7NvFogC", "citedby": "14"}, {"bib": {"title": "Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients \u2026", "year": "2010"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:q3oQSFYPqjQC", "citedby": "14"}, {"bib": {"title": "Calreticulin promotes immunity and type I interferon-dependent survival in mice with acute myeloid leukemia", "year": "2017"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:dhFuZR0502QC", "citedby": "12"}, {"bib": {"title": "T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for \u2026", "year": "2011"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:kRWSkSYxWN8C", "citedby": "12"}, {"bib": {"title": "Phase I Results of Combination Gemcitabine and Bortezomib (Velcade\u00ae) for Relapsed/Refractory Nodal T-Cell Non-Hodgkin Lymphoma (T-NHL) and Aggressive B-Cell NHL (B-NHL).", "year": "2008"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:NMxIlDl6LWMC", "citedby": "12"}, {"bib": {"title": "PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell\u2013inflamed phenotype", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:7PzlFSSx8tAC", "citedby": "11"}, {"bib": {"title": "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia", "year": "2016"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:u9iWguZQMMsC", "citedby": "10"}, {"bib": {"title": "No exit: identifying avoidable terminal oncology intensive care unit hospitalizations", "year": "2016"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:g5m5HwL7SMYC", "citedby": "10"}, {"bib": {"title": "Frequency and risk factors associated with cord graft failure after transplant with single-unit umbilical cord cells supplemented by haploidentical cells with reduced-intensity \u2026", "year": "2016"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:SP6oXDckpogC", "citedby": "10"}, {"bib": {"title": "A phase 2 study of epothilone B analog BMS\u2010247550 (NSC 710428) in patients with relapsed aggressive non\u2010Hodgkin lymphomas", "year": "2013"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:4DMP91E08xMC", "citedby": "10"}, {"bib": {"title": "Reduced-intensity allogeneic transplant for acute myeloid leukemia and myelodysplastic syndrome using combined CD34-selected haploidentical graft and a single umbilical cord \u2026", "year": "2018"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:3s1wT3WcHBgC", "citedby": "9"}, {"bib": {"title": "Severe intestinal graft-versus-host disease following autologous stem cell transplantation", "year": "2006"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:NaGl4SEjCO4C", "citedby": "9"}, {"bib": {"title": "Chimerism does not predict for outcome after alemtuzumab based conditioning", "year": "2007"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:08ZZubdj9fEC", "citedby": "7"}, {"bib": {"title": "Nelarabine in the treatment of refractory T-cell malignant diseases", "year": "2006"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:ufrVoPGSRksC", "citedby": "7"}, {"bib": {"title": "Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:Mojj43d5GZwC", "citedby": "6"}, {"bib": {"title": "Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation for high-risk lymphoma and chronic lymphoblastic leukemia", "year": "2018"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:uWQEDVKXjbEC", "citedby": "6"}, {"bib": {"title": "Prospective phase I multi-center trial incorporating lenalidomide (LEN) into dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in patients with double hit (DHL) or double \u2026", "year": "2016"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:2P1L_qKh6hAC", "citedby": "6"}, {"bib": {"title": "Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:dQ2og3OwTAUC", "citedby": "5"}, {"bib": {"title": "Immune profiles in primary squamous cell carcinoma of the head and neck", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:AXPGKjj_ei8C", "citedby": "5"}, {"bib": {"title": "CD8\u03b1+ dendritic cells dictate leukemia-specific CD8+ T cell fates", "year": "2018"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:W7OEmFMy1HYC", "citedby": "5"}, {"bib": {"title": "Phase I trial of temsirolimus and lenalidomide in pts with rel/ref lymphomas.", "year": "2012"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:4TOpqqG69KYC", "citedby": "5"}, {"bib": {"title": "Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab (CMA) Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Advanced Hematologic \u2026", "year": "2009"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:l7t_Zn2s7bgC", "citedby": "5"}, {"bib": {"title": "Allogeneic Hematopoietic Cell Transplantation From Combined Haploidentical Family Members and Unrelated Cord Blood (CB) Can Benefit High Risk Patients Lacking HLA-Identical Donors.", "year": "2009"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:MXK_kJrjxJIC", "citedby": "5"}, {"bib": {"title": "Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:9vf0nzSNQJEC", "citedby": "4"}, {"bib": {"title": "THE FIRST\u2010IN\u2010CLASS ANTI\u2010CD47 ANTIBODY HU5F9\u2010G4+ RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:bnK-pcrLprsC", "citedby": "4"}, {"bib": {"title": "Pembrolizumab for the treatment of disease relapse following allogeneic hematopoietic cell transplantation", "year": "2018"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:35N4QoGY0k4C", "citedby": "4"}, {"bib": {"title": "31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two", "year": "2016"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:M05iB0D1s5AC", "citedby": "4"}, {"bib": {"title": "MYC\u2014a thorn in the side of cancer immunity", "year": "2016"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:dshw04ExmUIC", "citedby": "4"}, {"bib": {"title": "Haplo-cord UCB SCT with low cell dose, well matched UCB Units. A prospective multicenter study", "year": "2014"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:D03iK_w7-QYC", "citedby": "4"}, {"bib": {"title": "Haplo-cord transplantation vs unrelated donor stem cell transplantation in patients with AML/MDS older than 50", "year": "2014"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:isC4tDSrTZIC", "citedby": "4"}, {"bib": {"title": "Peripheral T-cell tolerance in hosts with acute myeloid leukemia", "year": "2013"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:1qzjygNMrQYC", "citedby": "4"}, {"bib": {"title": "The immune landscape and response to immune checkpoint blockade therapy in lymphoma", "year": "2020"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:UHK10RUVsp4C", "citedby": "3"}, {"bib": {"title": "Phase 1 study of lenalidomide plus dose\u2010adjusted EPOCH\u2010R in patients with aggressive B\u2010cell lymphomas with deregulated MYC and BCL2", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:sSrBHYA8nusC", "citedby": "3"}, {"bib": {"title": "Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment", "year": "2016"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:e5wmG9Sq2KIC", "citedby": "3"}, {"bib": {"title": "Activation of the STING pathway enhances immunity and improves survival in a murine myeloid leukemia model", "year": "2014"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:cFHS6HbyZ2cC", "citedby": "3"}, {"bib": {"title": "Temsirolimus (TEM) and lenalidomide (LEN) in relapsed/refractory Hodgkin lymphoma including in patients with prior exposure to brentuximab vedotin (BV).", "year": "2014"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:QIV2ME_5wuYC", "citedby": "3"}, {"bib": {"title": "Geriatric assessment (GA) to predict survival in older allogeneic hematopoietic cell transplantation (HCT) recipients", "year": "2014"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:UxriW0iASnsC", "citedby": "3"}, {"bib": {"title": "CD8\u03b1+ dendritic cells dictate immune responses against murine AML", "year": "2013"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:lSLTfruPkqcC", "citedby": "3"}, {"bib": {"title": "Novel immunotherapy to eliminate minimal residual disease in AML patients", "year": "2013"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:blknAaTinKkC", "citedby": "3"}, {"bib": {"title": "Features of frailty are surprisingly common in adults 50 years and older undergoing allogeneic hematopoietic cell transplantation (HCT) in the modern era", "year": "2011"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:yD5IFk8b50cC", "citedby": "3"}, {"bib": {"title": "A phase I trial evaluating the safety and biological activity of iboctadekin (rhIL-18) in combination with rituximab in patients with CD20+ B-cell non-Hodgkin's lymphoma", "year": "2009"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:LkGwnXOMwfcC", "citedby": "3"}, {"bib": {"title": "Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:1yQoGdGgb4wC", "citedby": "2"}, {"bib": {"title": "Negligible Role for Deletion Mediated by cDC1 in CD8+ T Cell Tolerance", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:maZDTaKrznsC", "citedby": "2"}, {"bib": {"title": "PD-L1 gene alterations identify a unique subset of diffuse large B cell lymphoma that harbors a T cell inflamed phenotype", "year": "2018"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:B3FOqHPlNUQC", "citedby": "2"}, {"bib": {"title": "Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial", "year": "2018"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:_FxGoFyzp5QC", "citedby": "2"}, {"bib": {"title": "31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one", "year": "2016"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:j3f4tGmQtD8C", "citedby": "2"}, {"bib": {"title": "Correlation of specific genetic aberrations and signaling pathways with T-cell inflamed phenotype (TCIP) in head and neck cancer and as novel candidate biomarkers for \u2026", "year": "2015"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:_xSYboBqXhAC", "citedby": "2"}, {"bib": {"title": "Pilot study of regulatory T cell depletion in the setting of autologous stem cell transplantation for multiple myeloma", "year": "2013"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:ZeXyd9-uunAC", "citedby": "2"}, {"bib": {"title": "Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Advanced Hematologic Malignancies \u2026", "year": "2009"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:mVmsd5A6BfQC", "citedby": "2"}, {"bib": {"title": "Will changing the face of WT1 make it more attractive to T cells?", "year": "2009"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:IjCSPb-OGe4C", "citedby": "2"}, {"bib": {"title": "Preliminary results of combined haploidentical-cord blood transplantation for patients lacking HLA identical donors", "year": "2008"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:hFOr9nPyWt4C", "citedby": "2"}, {"bib": {"title": "Ganciclovir and high-dose valacyclovir reduce cytomegalovirus reactivation in patients receiving allogeneic stem cell transplantation with Campath-1H\u2013based conditioning regimens", "year": "2005"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:_Qo2XoVZTnwC", "citedby": "2"}, {"bib": {"title": "Calreticulin arms NK cells against leukemia", "year": "2020"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:eq2jaN3J8jMC", "citedby": "1"}, {"bib": {"title": "Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the \u2026", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:qxL8FJ1GzNcC", "citedby": "1"}, {"bib": {"title": "Romidepsin and total skin electron beam therapy in advanced stage mycosis fungoides and S\u00e9zary syndrome", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:qUcmZB5y_30C", "citedby": "1"}, {"bib": {"title": "Phase II study of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas: final analysis of NCI 8309", "year": "2016"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:KxtntwgDAa4C", "citedby": "1"}, {"bib": {"title": "A phase 1/2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas (NHLs).", "year": "2016"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:Tyk-4Ss8FVUC", "citedby": "1"}, {"bib": {"title": "Selection and Monitoring of Patients for Immunotherapy (Peptide Vaccines)", "year": "2015"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:TFP_iSt0sucC", "citedby": "1"}, {"bib": {"title": "A Phase I/II Trial of Combination Gemcitabine and Bortezomib (VELCADE\u00ae) for Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma (NHL) and Aggressive B-Cell NHL", "year": "2011"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:J_g5lzvAfSwC", "citedby": "1"}, {"bib": {"title": "A Phase I/II Trial of Combination Gemcitabine and Bortezomib (VEL-CADE (R)) for Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma (NHL) and Aggressive B-Cell NHL", "year": "2011"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:9ZlFYXVOiuMC", "citedby": "1"}, {"bib": {"title": "Pharmacokinetics and assessment of renal toxicity of a clofarabine (Clo), melphalan (Mel), and alemtuzumab (Alm) conditioning regimen.", "year": "2010"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:Wp0gIr-vW9MC", "citedby": "1"}, {"bib": {"title": "Alemtuzumab-Containing Allogeneic Hematopoietic Cell Transplant (HCT) for Relapsed Lymphomas: Prognostic Factors and Outcome.", "year": "2009"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:UeHWp8X0CEIC", "citedby": "1"}, {"bib": {"title": "Phase I Results of Combination Gemcitabine and Bortezomib (Velcade (R)) for Relapsed/Refractory Nodal T-Cell Non-Hodgkin Lymphoma (T-NHL) and Aggressive B-Cell NHL (B-NHL)", "year": "2008"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:4fKUyHm3Qg0C", "citedby": "1"}, {"bib": {"title": "Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation (Hct) in Patients with Advanced Hematologic Malignancies: A Phase I\u2013II Study", "year": "2008"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:YOwf2qJgpHMC", "citedby": "1"}, {"bib": {"title": "Diagnostic utility of STAT6 YE361 expression in classical Hodgkin lymphoma and related entities", "year": "2020"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:uLbwQdceFCQC", "citedby": "0"}, {"bib": {"title": "Abstract B96: Calreticulin exposure on malignant blasts correlates with improved NK cell-mediated cytotoxicity in AML patients", "year": "2020"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:tKAzc9rXhukC", "citedby": "0"}, {"bib": {"title": "Recommendations from a Geriatric Assessment (GA) Guided Multidisciplinary Clinic (MDC) in Older Patients for Autologous Hematopoietic Cell Transplant (autoHCT)", "year": "2020"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:Fu2w8maKXqMC", "citedby": "0"}, {"bib": {"title": "Gal9/Tim-3 expression level is higher in patient with failed chemotherapy in AML", "year": "2020"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:ZfRJV9d4-WMC", "citedby": "0"}, {"bib": {"title": "Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation", "year": "2020"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:NJ774b8OgUMC", "citedby": "0"}, {"bib": {"title": "Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in \u2026", "year": "2020"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:kzcrU_BdoSEC", "citedby": "0"}, {"bib": {"title": "Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study", "year": "2020"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:_Ybze24A_UAC", "citedby": "0"}, {"bib": {"title": "The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or \u2026", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:W5xh706n7nkC", "citedby": "0"}, {"bib": {"title": "Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:hkOj_22Ku90C", "citedby": "0"}, {"bib": {"title": "Resistance to Axicabtagene Ciloleucel Therapy in T Cell/Histiocyte-Rich Large B Cell Lymphoma", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:PR6Y55bgFSsC", "citedby": "0"}, {"bib": {"title": "Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:ZuybSZzF8UAC", "citedby": "0"}, {"bib": {"title": "Integrative Immunogenomic Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune Landscapes", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:N5tVd3kTz84C", "citedby": "0"}, {"bib": {"title": "Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCL", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:VL0QpB8kHFEC", "citedby": "0"}, {"bib": {"title": "Divergent fates of antigen-specific CD8+ T cell clones in mice with acute myeloid leukemia", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:JQOojiI6XY0C", "citedby": "0"}, {"bib": {"title": "Nivolumab Combined with Brentuximab Vedotin (BV) for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (R/R PMBL): Efficacy and Safety Results from the Phase 2 \u2026", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:JoZmwDi-zQgC", "citedby": "0"}, {"bib": {"title": "Type I Interferon Signaling Predicts Inferior Survival in Patients with AML", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:PELIpwtuRlgC", "citedby": "0"}, {"bib": {"title": "Investigating the Role of the Immune Checkpoint Receptor TIGIT in Lymphoma", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:_B80troHkn4C", "citedby": "0"}, {"bib": {"title": "NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: EFFICACY AND SAFETY RESULTS FROM THE PHASE 2 CHECKMATE 436 STUDY \u2026", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:XiVPGOgt02cC", "citedby": "0"}, {"bib": {"title": "Dendritic cells present cancer-derived p: MHCI molecules to prime anti-tumor CD8 T cells", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:WA5NYHcadZ8C", "citedby": "0"}, {"bib": {"title": "The fate of leukemia-specific CD8+ T cell clones is dictated by antigen specificity and the mechanism of cognate antigen presentation", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:HE397vMXCloC", "citedby": "0"}, {"bib": {"title": "Loss of 5-Hydroxymethylcytosine (5-hmC) Expression is Near-Universal in B-Cell Lymphomas", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:Y5dfb0dijaUC", "citedby": "0"}, {"bib": {"title": "Pilot Study of Regulatory T-Cell Depletion in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:fPk4N6BV_jEC", "citedby": "0"}, {"bib": {"title": "Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:nb7KW1ujOQ8C", "citedby": "0"}, {"bib": {"title": "Diagnostic utility of STAT6", "year": "2019"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:7T2F9Uy0os0C", "citedby": "0"}, {"bib": {"title": "Development of Acute Myeloid Leukemia Cell Membrane Coated Nanoparticles (AMCNPs) for Cancer Vaccination Immunotherapy", "year": "2018"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:geHnlv5EZngC", "citedby": "0"}, {"bib": {"title": "Procalcitonin As a Potential Biomarker for Differentiating Bacterial Infectious Fevers from Cytokine Release Syndrome", "year": "2018"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:Y0pCki6q_DkC", "citedby": "0"}, {"bib": {"title": "Pd-l1 gene alterations identify a subset of diffuse large B cell lymphoma harboring a T cell inflamed phenotype", "year": "2018"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:eQOLeE2rZwMC", "citedby": "0"}, {"bib": {"title": "Pd-l1 gene alterations to identify a subset of diffuse large B cell lymphoma that harbor a T cell inflamed phenotype.", "year": "2018"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:olpn-zPbct0C", "citedby": "0"}, {"bib": {"title": "Profiling the immune checkpoint pathway in acute myeloid leukemia.", "year": "2018"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:mB3voiENLucC", "citedby": "0"}, {"bib": {"title": "Characterization of the immunogenomic landscape of follicular lymphoma.", "year": "2018"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:qjMakFHDy7sC", "citedby": "0"}, {"bib": {"title": "Outcomes after Alemtuzumab-Based Conditioning Therapy and Allogeneic Transplantation for Lymphoid Malignancies", "year": "2018"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:8AbLer7MMksC", "citedby": "0"}, {"bib": {"title": "Dose Escalation Prophylactic Donor Lymphocyte Infusion (pDLI) after T-Cell Depleted (TCD) Matched Related Donor (MRD) Allogeneic Hematopoietic Cell Transplantation (Allo-HCT \u2026", "year": "2017"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:VOx2b1Wkg3QC", "citedby": "0"}, {"bib": {"title": "Validation of Pre-Transplant Biomarker Measurement and Risk Score for Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant (HCT)", "year": "2017"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:xtRiw3GOFMkC", "citedby": "0"}, {"bib": {"title": "Characterization of the Immunogenomic Landscape of Follicular Lymphoma", "year": "2017"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:hMod-77fHWUC", "citedby": "0"}, {"bib": {"title": "AML1/ETO and FLT3-ITD Cooperate to Induce Acute Myeloid Leukemia in Mice", "year": "2017"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:roLk4NBRz8UC", "citedby": "0"}, {"bib": {"title": "Cross-dressed dendritic cells drive anti-tumor immunity", "year": "2017"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:5ugPr518TE4C", "citedby": "0"}, {"bib": {"title": "Investigating the specificity and response of a native leukemia-reactive CD8 (+) T cell clone", "year": "2017"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:wbdj-CoPYUoC", "citedby": "0"}, {"bib": {"title": "Role of Ddx41 in the Stimulator of Interferon Genes (STING) Pathway", "year": "2017"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:0EnyYjriUFMC", "citedby": "0"}, {"bib": {"title": "CheckMate 436: A phase 1-2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas.", "year": "2017"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:EUQCXRtRnyEC", "citedby": "0"}, {"bib": {"title": "The R function for obtaining the empirical likelihood ratio confidence interval estimation of best linear combinations of biomarkers", "year": "2016"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:t6usbXjVLHcC", "citedby": "0"}, {"bib": {"title": "Excellent Clinical Outcome for Relapsed and Refractory Lymphoma Patients with Haplo-Cord Allogeneic Stem Cell Transplantation", "year": "2016"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:XiSMed-E-HIC", "citedby": "0"}, {"bib": {"title": "Comorbidity from Solid Tumor or Hematologic Malignancy Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) May Both Increase Non-Relapse Mortality", "year": "2016"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:Zph67rFs4hoC", "citedby": "0"}, {"bib": {"title": "53TiPPembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma: Randomized phase 3 KEYNOTE-204 study", "year": "2016"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:ldfaerwXgEUC", "citedby": "0"}, {"bib": {"title": "PEMBROLIZUMAB VERSUS BRENTUXIMAB VEDOTIN IN RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: RANDOMIZED, PHASE 3 KEYNOTE-204 STUDY", "year": "2016"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:1sJd4Hv_s6UC", "citedby": "0"}, {"bib": {"title": "Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (cHL): randomized phase 3 KEYNOTE-204 study", "year": "2016"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:d1gkVwhDpl0C", "citedby": "0"}, {"bib": {"title": "Feasibility of early withdrawal of immunosuppression (WOI) followed by dose escalation of prophylactic donor lymphocyte infusion (pDLI) after T-cell depleted (TCD) matched \u2026", "year": "2016"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:ns9cj8rnVeAC", "citedby": "0"}, {"bib": {"title": "Evaluation of a pre-transplant serum biomarker score for allogeneic hematopoietic stem cell transplant (HCT) and association with clinical factors.", "year": "2016"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:_kc_bZDykSQC", "citedby": "0"}, {"bib": {"title": "CD8\u03b1+ Dendritic Cells Induce Leukemia-Specific T cell Tolerance", "year": "2016"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:p2g8aNsByqUC", "citedby": "0"}, {"bib": {"title": "STING PATHWAY ACTIVATION ENHANCES IMMUNE RESPONSE AND IMPROVES SURVIVAL IN MURINE MYELOID LEUKEMIA.: PII-087", "year": "2016"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:5nxA0vEk-isC", "citedby": "0"}, {"bib": {"title": "Abstract A10: Activation of the STING pathway enhances immunity and improves survival in a murine myeloid leukemia model.", "year": "2015"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:3fE2CSJIrl8C", "citedby": "0"}, {"bib": {"title": "Diversity of CD8+ and rgulatory T cells is inversely correlated in follicular lymphoma: A potential predictive biomarker", "year": "2015"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:RYcK_YlVTxYC", "citedby": "0"}, {"bib": {"title": "Exploratory analysis of clinical and translational factors associated with the inflamed phenotype in HNSCC.", "year": "2015"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:r0BpntZqJG4C", "citedby": "0"}, {"bib": {"title": "Dendritic cells coordinate the development and homeostasis of organ-specific regulatory T cells (LYM2P. 730)", "year": "2015"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:u_35RYKgDlwC", "citedby": "0"}, {"bib": {"title": "The Outcomes of Second Allogeneic Stem Cell Transplantation for Disease Relapse after T Cell Depleted Allogeneic Stem Cell Transplantation: A Single Center Experience \u2026", "year": "2014"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:abG-DnoFyZgC", "citedby": "0"}, {"bib": {"title": "Frequency and Risk Factors of Cord Graft Failure (CGF) Following Reduced Intensity Conditioning Haplo-Cord Hematopoietic Stem Cell Transplantation", "year": "2014"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:b0M2c_1WBrUC", "citedby": "0"}, {"bib": {"title": "Incidence and Predictors of Respiratory Viral Infections By Multi-Plex PCR in Allogeneic Hematopoietic Cell Transplant (HCT) Recipients 50 Years and Older Including Geriatric \u2026", "year": "2014"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:R3hNpaxXUhUC", "citedby": "0"}, {"bib": {"title": "Calreticulin Promotes Immunity Against Acute Myeloid Leukemia Cells in Vivo", "year": "2014"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:KlAtU1dfN6UC", "citedby": "0"}, {"bib": {"title": "Post-Transplant Lymphoproliferative Disorder Is Common after Reduced-Intensity ATG Conditioning and Haplo-Cord Transplantation", "year": "2014"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:rO6llkc54NcC", "citedby": "0"}, {"bib": {"title": "In Vivo Targeting Of Acute Myeloid Leukemia Using CpG-Stat3 siRNA Results In T Cell-Dependent Tumor Eradication", "year": "2013"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:4JMBOYKVnBMC", "citedby": "0"}, {"bib": {"title": "Calreticulin mediates immune recognition of acute myeloid leukemia cells in vivo", "year": "2013"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:mvPsJ3kp5DgC", "citedby": "0"}, {"bib": {"title": "Role of the PD-1/PD-L1 Pathway on Regulatory T Cell Development, Induction and Function in vivo", "year": "2012"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:YFjsv_pBGBYC", "citedby": "0"}, {"bib": {"title": "Host ephrinB2 regulates T-cells in tumor microenvironments", "year": "2012"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:ULOm3_A8WrAC", "citedby": "0"}, {"bib": {"title": "Listen to Thy Patient: Poor Quality of Life (QoL) Reported by Older Adults Prior to Allogeneic Stem Cell Transplantation (allo-HCT) Is Independently Associated with Worse \u2026", "year": "2012"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:M3ejUd6NZC8C", "citedby": "0"}, {"bib": {"title": "Reduced Intensity Conditioning with Combined Haploidentical and Cord Blood Transplantation Results in Rapid Engraftment and Durable Remissions in Hematological Malignancies", "year": "2011"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:D_sINldO8mEC", "citedby": "0"}, {"bib": {"title": "Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation: Final Report of a Phase I-II Study", "year": "2011"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:WbkHhVStYXYC", "citedby": "0"}, {"bib": {"title": "Reduced intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engrafment and durable remissions.", "year": "2011"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:bEWYMUwI8FkC", "citedby": "0"}, {"bib": {"title": "Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation", "year": "2011"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:Tiz5es2fbqcC", "citedby": "0"}, {"bib": {"title": "Reduced-intensity haplo cord transplant: O160", "year": "2011"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:k_IJM867U9cC", "citedby": "0"}, {"bib": {"title": "Interferon-beta Secretion in the Tumor Microenvironment can Cause Potent Tumor Control Through Host Cells Independently from Adaptive Immunity", "year": "2010"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:RGFaLdJalmkC", "citedby": "0"}, {"bib": {"title": "A State of Dominant Tolerance is Rapidly Induced with Intravenous Dissemination but not with Subcutaneous Implantation in a Murine Leukemia Model", "year": "2010"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:hqOjcs7Dif8C", "citedby": "0"}, {"bib": {"title": "Clofarabine-melphalan-alemtuzumab conditioning for allogeneic haematopoietic cell transplantation in advanced haematologic malignancies. Immunosuppression and long-term \u2026", "year": "2010"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:O3NaXMp0MMsC", "citedby": "0"}, {"bib": {"title": "Can We Do Better In Management Of Neutropenic Fever In Hematological Patients?", "year": "2010"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:u5HHmVD_uO8C", "citedby": "0"}, {"bib": {"title": "Cellular and Molecular Requirements for Rejection of B16 Melanoma in the Setting of Regulatory T-cell Depletion and Homeostatic Proliferation", "year": "2009"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:738O_yMBCRsC", "citedby": "0"}, {"bib": {"title": "Phase II Study of GM-CSF, IL-2 and Rituximab Immunomodulation Following Autologous Stem Cell Transplantation in Patients with Relapsed or Refractory Lymphomas", "year": "2008"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:L8Ckcad2t8MC", "citedby": "0"}, {"bib": {"title": "Blockade of PD-1/PD-L1 Interactions is Paradoxically Detrimental in a T Cell Adoptive Transfer Tumor Therapy Model", "year": "2008"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:a0OBvERweLwC", "citedby": "0"}, {"bib": {"title": "Adoptive Transfer of CD25-Depleted Polyclonal T Cells Into Lymphopenic Hosts Promotes Spontaneous Tumor Rejection", "year": "2006"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:YsMSGLbcyi4C", "citedby": "0"}, {"bib": {"title": "The relationship of day 30 and day 100 donor chimerism to clinical outcomes following reduced-intensity allogeneic transplantation for hematologic malignancies", "year": "2006"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:eJXPG6dFmWUC", "citedby": "0"}, {"bib": {"title": "Alemtuzumab (Campath 1-H) Exposure Correlates with Risk of Chronic Graft vs Host Disease and CMV Viremia after Allogeneic Transplantation.", "year": "2005"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:HoB7MX3m0LUC", "citedby": "0"}, {"bib": {"title": "Streaming-data algorithms for high-quality clustering.", "year": "2005"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:JV2RwH3_ST0C", "citedby": "0"}, {"bib": {"title": "Conditioning with Fludarabine (Flu)-Alkylator Is More Effective Cytoreduction Than Cyclophosphamide-Total Body Irradiation (Cy/TBI) for Refractory, Progressive Chronic \u2026", "year": "2004"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:u-x6o8ySG0sC", "citedby": "0"}, {"bib": {"title": "Impact of disease burden at time of allogeneic stem cell transplantation (SCT) in adults with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).", "year": "2003"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:fQNAKQ3IYiAC", "citedby": "0"}, {"bib": {"title": "PILOT STUDY OF PROPHYLACTIC DOSE-ESCALATION DONOR LYMPHOCYTE INFUSION AFTER T CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANT IN HIGH RISK PATIENTS WITH HEMATOLOGIC MALIGNANCIES"}, "source": "citations", "id_citations": "UgD1uFgAAAAJ:ye4kPcJQO24C", "citedby": "0"}]}